[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Mula V, Mandal A, Britton E, Shanker VS: Direct bony invasion of malignant melanoma. Indian J Orthop; 2009 Oct;43(4):420-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct bony invasion of malignant melanoma.
  • Malignant melanoma is known to spread by local extention, by the lymphatics by the blood stream.
  • Direct invasion of the bone from a cutaneous melanoma is unknown.
  • Histopathology diagnosed the lesion as locally advanced malignant melanoma.
  • Radiological investigations by X-ray and magnetic resonance imaging revealed malignant infiltration of the tibia in its mid and lower third with two soft tissue metastatic masses adjacent.
  • Histology following amputation confirmed malignant melanoma with cranial resection margin involvement.
  • She underwent a further above-knee amputation followed by chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Orthopedics. 2001 Mar;24(3):225, 307-8 [11300284.001]
  • [Cites] J Bone Joint Surg Am. 2001 Nov;83-A(11):1713-7 [11701796.001]
  • [Cites] Arch Pathol Lab Med. 2000 Dec;124(12):1780-4 [11100057.001]
  • [Cites] J Laryngol Otol. 2000 May;114(5):378-80 [10912271.001]
  • [Cites] Can J Surg. 2000 Apr;43(2):137-9 [10812349.001]
  • [Cites] J Hand Surg Am. 2000 Mar;25(2):365-9 [10722831.001]
  • [Cites] Int J Clin Oncol. 2007 Aug;12(4):305-8 [17701013.001]
  • [Cites] Ear Nose Throat J. 2007 Jul;86(7):388-90 [17702316.001]
  • [Cites] J Cutan Med Surg. 2006 Jan-Feb;10(1):36-40 [17241571.001]
  • [Cites] Europace. 2006 Jul;8(7):545-8 [16798769.001]
  • [Cites] Am Surg. 2006 Jan;72(1):98-100 [16494196.001]
  • [Cites] J Hand Surg Am. 2005 May;30(3):615-9 [15925176.001]
  • [Cites] Ann Surg Oncol. 1999 Jun;6(4):336-44 [10379853.001]
  • [Cites] Arch Pathol Lab Med. 1999 Feb;123(2):163-6 [10050793.001]
  • [Cites] J Laryngol Otol. 2004 May;118(5):382-4 [15165318.001]
  • [Cites] J Hand Surg Am. 2004 Mar;29(2):194-200 [15043888.001]
  • [Cites] Clin Nucl Med. 2003 Dec;28(12):961-5 [14663316.001]
  • [Cites] Mol Imaging Biol. 2002 Oct;4(5):359-62 [14537111.001]
  • [Cites] Rom J Gastroenterol. 2002 Mar;11(1):53-6 [12096315.001]
  • [Cites] J Hand Surg Am. 2000 Nov;25(6):1169-72 [11119681.001]
  • (PMID = 19838397.001).
  • [ISSN] 1998-3727
  • [Journal-full-title] Indian journal of orthopaedics
  • [ISO-abbreviation] Indian J Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2762569
  • [Keywords] NOTNLM ; Bone tumor / direct invasion / malignant melanoma / metastatic melanoma
  •  go-up   go-down


2. Ludwig RJ, Boehme B, Podda M, Henschler R, Jager E, Tandi C, Boehncke WH, Zollner TM, Kaufmann R, Gille J: Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res; 2004 Apr 15;64(8):2743-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis.
  • Whereas previous attention has focused on P-selectin-dependent tumor-cell-platelet interactions in blood-borne metastasis, we sought to address the potential contribution of endothelial P-selectin expression to adhesive events between the microvasculature and melanoma cells in vivo.
  • Transplantation of bone marrow from P-selectin-deficient into wild-type mice conveyed inhibition of ex-perimental melanoma metastasis.
  • However, the extent to which bone marrow-conferred lack of platelet P-selectin expression attenuated melanoma lung metastasis was significantly less than that seen in P-selectin-deficient mice, suggesting that endothelial P-selectin expression may additionally contribute to formation of hematogenous metastases.
  • This assumption was supported by our intravital microscopy studies, in which a significant proportion of melanoma cells were capable of directly interacting with postcapillary venules of the murine ear in a P-selectin-dependent manner.
  • Heparin not only inhibits P-selectin-mediated melanoma cell rolling but also attenuates melanoma metastasis formation in vivo, further supporting the concept that endothelial P-selectin expression may represent an additional target of heparin action in experimental melanoma lung metastasis.
  • [MeSH-major] Heparin / pharmacology. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Melanoma / drug therapy. Melanoma / secondary. P-Selectin / blood
  • [MeSH-minor] Animals. Blood Platelets / metabolism. Cell Communication / drug effects. Cell Communication / physiology. Endothelium, Vascular / drug effects. Endothelium, Vascular / pathology. Humans. Male. Melanoma, Experimental / blood. Melanoma, Experimental / drug therapy. Melanoma, Experimental / pathology. Melanoma, Experimental / secondary. Mice. Mice, Inbred C57BL. Neoplasm Transplantation


3. Ely H, Pascucci A: Merkel cell carcinoma: treatment with bleomycin. Dermatol Online J; 2008;14(9):3
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma: treatment with bleomycin.
  • Merkel cell carcinoma is the second most deadly form of skin cancer after melanoma, with a mortality rate of as high as 35 percent.
  • Surgery, followed by radiation therapy is the standard of treatment.
  • Chemotherapy, such as is used for oat cell carcinoma of the lung, is advised for metastatic disease.
  • However, systemic chemotherapy protocols have not been overly successful.
  • Bleomycin, besides being a potent chemotherapy agent, has direct antiviral effects that may explain why this drug is so effective in treating Merkel cell carcinoma.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Carcinoma, Merkel Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged, 80 and over. Combined Modality Therapy. Ear Neoplasms / drug therapy. Facial Neoplasms / drug therapy. Facial Neoplasms / pathology. Facial Neoplasms / radiotherapy. Female. Follow-Up Studies. Humans. Injections, Intralesional. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Remission Induction

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19061585.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


Advertisement
4. Kudchadkar R, Gonzalez R, Robinson W, Becker M, Treichel K, Kimura A, Lewis K: The absent-minded professor: an unusual complication of melanoma. Oncology (Williston Park); 2008 Dec;22(14):1609-14
MedlinePlus Health Information. consumer health - Retinal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The absent-minded professor: an unusual complication of melanoma.
  • [MeSH-major] Brain Neoplasms / complications. Brain Neoplasms / secondary. Ear Neoplasms / drug therapy. Melanoma / complications. Retinal Diseases / etiology
  • [MeSH-minor] Anti-Inflammatory Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Dementia / etiology. Humans. Immunoglobulins, Intravenous / therapeutic use. Immunologic Factors / therapeutic use. Interferons / therapeutic use. Male. Middle Aged. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19198219.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents; 0 / Immunoglobulins, Intravenous; 0 / Immunologic Factors; 9008-11-1 / Interferons
  •  go-up   go-down


5. Boursault L, Scasso A, Laumonier H, Lalanne N, Versapuech J, Taieb A, Jouary T: [Two cases of pulmonary melanoma metastasis treated with radiofrequency: An alternative to surgical excision]. Ann Dermatol Venereol; 2010 Dec;137(12):799-802
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of pulmonary melanoma metastasis treated with radiofrequency: An alternative to surgical excision].
  • [Transliterated title] Deux cas de métastases pulmonaires de mélanome traitées par radiofréquence : une alternative à la chirurgie.
  • BACKGROUND: based on consensual recommendations, surgery remains the standard treatment for curable lung metastases.
  • We report herein two patients presenting with low-burden lung metastases from malignant melanoma treated by radiofrequency.
  • PATIENTS AND METHODS: two patients presented with one to two limited burden lung metastases from malignant melanoma, respectively.
  • Both patients received neoadjuvant chemotherapy leading to disease stabilization, after which the lung metastases were treated by radiofrequency.
  • DISCUSSION: surgical treatment of solitary or scant pulmonary metastases from melanoma has proved its efficacy with a gain in overall and disease-free survival.
  • Nevertheless, this treatment cannot be proposed in patients with contraindications for anaesthesia or compromised pulmonary function.
  • [MeSH-major] Catheter Ablation. Ear Neoplasms / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Melanoma / secondary. Melanoma / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Postoperative Complications / etiology. Postoperative Complications / radiography. Postoperative Complications / surgery. Reoperation. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 21134583.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


6. García González LA, Redondo Ventura F: [Metastases in both internal auditive meatus of nasosinusal melanoma]. An Otorrinolaringol Ibero Am; 2005;32(6):537-44
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastases in both internal auditive meatus of nasosinusal melanoma].
  • [Transliterated title] Metastasis en ambos conductos auditivos internos de melanoma nasosinusal. A propósito de un caso.
  • Primary malignant melanoma of the nasal and paranasal sinusses is rare and represent 3% of malignant nasosinusal tumors.
  • Chemotherapy is used for metastatic forms.
  • We present a case of a patient with a primary malignant melanoma of the nasal mucosa.
  • [MeSH-major] Ear Neoplasms / secondary. Ear, Inner / pathology. Melanoma / secondary. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16475540.001).
  • [ISSN] 0303-8874
  • [Journal-full-title] Anales otorrinolaringológicos ibero-americanos
  • [ISO-abbreviation] An Otorrinolaringol Ibero Am
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


7. Baek SJ, Song MH, Lim BJ, Lee WS: Mucosal melanoma arising in the eustachian tube. J Laryngol Otol; 2006 Mar;120(3):E17
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosal melanoma arising in the eustachian tube.
  • Mucosal melanoma is a very rare disease.
  • To date,only three cases of melanoma originating from the eustachian tube have been reported.
  • We present a case of mucosal melanoma of eustachian tube origin in which a complete excision was performed.
  • Systemic chemotherapy was not utilized in this case; however, it is often used for palliative purposes.
  • [MeSH-major] Ear Neoplasms / pathology. Eustachian Tube / pathology. Melanoma / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Mucous Membrane / pathology. Mucous Membrane / surgery. Radiotherapy, Adjuvant / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16359579.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Aygenç E, Dakak Y, Ozdem C: [A case of auricular malignant melanoma]. Kulak Burun Bogaz Ihtis Derg; 2002 Jan-Feb;9(1):63-5
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of auricular malignant melanoma].
  • [Transliterated title] Auriküler malign melanoma.
  • We performed auricular excision, total parathyroidectomy, and extended radical neck dissection in a 36-year-old male patient who developed auricular malignant melanoma.
  • The patient received radiotherapy and chemotherapy after surgery.
  • [MeSH-major] Ear Neoplasms / surgery. Melanoma / surgery
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Diagnosis, Differential. Ear, External / surgery. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Neck Dissection. Parathyroidectomy. Radiotherapy, Adjuvant. Reconstructive Surgical Procedures. Skin Transplantation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12122628.001).
  • [ISSN] 1300-7475
  • [Journal-full-title] Kulak burun boğaz ihtisas dergisi : KBB = Journal of ear, nose, and throat
  • [ISO-abbreviation] Kulak Burun Bogaz Ihtis Derg
  • [Language] tur
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


9. Browning DJ, Perkins SL, Lark KK: Iris cyst secondary to latanoprost mimicking iris melanoma. Am J Ophthalmol; 2003 Mar;135(3):419-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iris cyst secondary to latanoprost mimicking iris melanoma.
  • PURPOSE: To report an ocular side effect of topical latanoprost therapy.
  • METHODS: A 73-year-old woman on latanoprost for primary open-angle glaucoma developed an iris cyst simulating an iris melanoma.
  • CONCLUSIONS: In managing patients with iris-pigmented lesions, the list of medications should be reviewed.
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Glaucoma, Open-Angle / drug therapy. Humans. Iris Neoplasms / diagnosis. Melanoma / diagnosis

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 by Elsevier Science Inc.
  • [CommentIn] Am J Ophthalmol. 2003 Oct;136(4):780; author reply 780-1 [14516849.001]
  • (PMID = 12614778.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 0 / Prostaglandins F, Synthetic; 6Z5B6HVF6O / latanoprost
  •  go-up   go-down


10. Lane AM, Egan KM, Harmon D, Holbrook A, Munzenrider JE, Gragoudas ES: Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis. Ophthalmology; 2009 Nov;116(11):2206-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis.
  • PURPOSE: To examine whether interferon (IFN)-alfa-2a treatment after radiation or enucleation reduces death rates in patients with uveal melanoma.
  • PARTICIPANTS: Subjects were identified through the ocular oncology clinic of the Massachusetts Eye and Ear Infirmary.
  • METHODS: Between May 1995 and June 1999, 121 patients with choroidal or ciliary body melanoma began a 2-year course of therapy (3 MIU IFN-alfa-2a subcutaneously 3 times per week), initiated within 3 years of primary therapy.
  • All patients underwent regular monitoring for drug toxicity.
  • To evaluate IFN-alfa-2a efficacy, we selected a series of historical controls frequency-matched (2:1) to IFN-alfa-2a-treated patients on age (+/-5 years), LTD (+/-3 mm), gender, and survival time between primary therapy and initiation of IFN therapy.
  • MAIN OUTCOME MEASURES: Melanoma-related mortality, metastasis, IFN-related toxicities.
  • RESULTS: Fifty-five patients (45%) completed therapy; the median dose for IFN-alfa-2a-treated patients was 792 MIU (85% of the theoretic dose).
  • The median follow-up time in the IFN-alfa-2a-treated group was approximately 9 years.
  • Treatment and control groups were similar with respect to age (P = 0.78), LTD (P = 0.38), and gender (P = 1.0).
  • Of 363 patients, 108 developed metastasis under observation; 42 of these were IFN-alfa-2a-treated patients.
  • Cumulative 5-year melanoma-related death rates were 17% in the radiation or enucleation-only group, 15% in those who completed the entire IFN-alfa-2a course, and 35% in those who discontinued IFN-alfa-2a therapy.
  • In multivariate Cox regression, IFN-alfa-2a had no significant influence on melanoma-related mortality (rate ratio = 1.02, 95% confidence interval, 0.68-1.5, P = 0.91) or all-cause mortality (rate ratio = 0.84, 95% confidence interval, 0.58-1.2, P = 0.34).
  • CONCLUSIONS: Interferon-alfa-2a has no material influence on survival in patients with choroidal melanoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Melanoma / drug therapy. Uveal Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Eye Enucleation. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Radiotherapy, Adjuvant. Recombinant Proteins. Risk Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ophthalmology. 2010 Sep;117(9):1861 [20816255.001]
  • (PMID = 19744725.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


11. Jacob A, Brightman RP, Welling DB: Bilateral cerebellopontine angle metastatic melanoma: a case report. Ear Nose Throat J; 2007 Jul;86(7):388-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral cerebellopontine angle metastatic melanoma: a case report.
  • Although melanoma accounts for approximately 1% of all malignancies, melanoma metastases to the cerebellopontine angles (CPAs) are exceedingly rare.
  • Here we describe a patient with melanoma metastases to the internal auditory canals and CPAs who presented with a remote history of cutaneous melanoma.
  • The diagnosis required a careful history, unilateral surgical resection for tissue acquisition, and histopathologic confirmation.
  • A search for primary cutaneous melanoma at the time of presentation was negative.
  • However, the history of cutaneous melanoma 8 years earlier distinguishes this patient's metastatic disease from solitary primary intracranial melanoma, an equally rare disease.
  • Treatment consists of surgical excision, radiation, chemotherapy, and immunotherapy.
  • The prognosis for patients with melanoma metastases is generally poor, but isolated reports of long-term survival have been described.
  • [MeSH-major] Cerebellar Neoplasms / secondary. Cerebellopontine Angle. Melanoma / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17702316.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Kumar S, Gupta AK, Yadav BS, Ghoshal S: Primary sinonasal malignant melanoma: a clinicopathologic and prognostic study. Ear Nose Throat J; 2009 Dec;88(12):1269-72
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sinonasal malignant melanoma: a clinicopathologic and prognostic study.
  • We conducted a retrospective study to evaluate the clinicopathologic features and prognostic factors associated with primary sinonasal malignant melanoma.
  • Medial maxillectomy was performed in 4 patients, wide local excision in 3, and endoscopic excision in 2; the remaining patient, who had presented with a liver metastasis, received chemotherapy and palliative local radiotherapy.
  • Based on the findings of our small study, we conclude that primary sinonasal malignant melanoma carries a generally poor prognosis despite aggressive treatment.
  • [MeSH-major] Melanoma / pathology. Melanoma / surgery. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20013681.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Maier H, Mühlmeier G, Kraft K, Blumstein NM, Tisch M: [Primary malignant melanoma of the parotid gland: a case report and review of the literature]. HNO; 2008 Jun;56(6):627-32
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary malignant melanoma of the parotid gland: a case report and review of the literature].
  • It is assumed that they originate in the glandular tissue or in intraglandular lymph nodes.
  • We present a case report and review of the literature on the diagnosis, treatment, and prognosis of intraparotid malignant melanoma.
  • Patients with a cytological diagnosis of MM are further evaluated by magnetic resonance imaging and positron emission tomography and receive a thorough ear-nose-throat and dermatological examination.
  • The treatment of choice is total parotidectomy and selective neck dissection.
  • The effectiveness of adjuvant treatments such as radiotherapy, chemotherapy, or immunotherapy remains controversial.
  • [MeSH-major] Melanoma / diagnosis. Melanoma / therapy. Parotid Neoplasms / diagnosis. Parotid Neoplasms / therapy
  • [MeSH-minor] Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] HNO. 2006 Mar;54(3):166-70 [16091908.001]
  • [Cites] Head Neck. 1997 Oct;19(7):589-94 [9323147.001]
  • [Cites] Laryngoscope. 1994 Oct;104(10):1194-8 [7934587.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1994 Apr;19(2):161-5 [8026097.001]
  • [Cites] Surg Gynecol Obstet. 1963 Sep;117:341-5 [14080349.001]
  • [Cites] Arch Surg. 1997 May;132(5):553-6 [9161401.001]
  • [Cites] Br J Plast Surg. 2001 Oct;54(7):636-7 [11583503.001]
  • [Cites] Am J Surg. 1985 Oct;150(4):510-2 [4051118.001]
  • [Cites] Laryngol Rhinol Otol (Stuttg). 1984 Jan;63(1):17-20 [6700327.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2001;13(6):466-9 [11824888.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1961 Jan;14:108-16 [13708292.001]
  • [Cites] Laryngorhinootologie. 2005 Jul;84(7):516-9 [16010634.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Jun;125(6):635-9 [10367919.001]
  • [Cites] Pathol Int. 1997 Aug;47(8):581-3 [9293542.001]
  • [Cites] Br J Oral Maxillofac Surg. 1993 Oct;31(5):313-5 [8218087.001]
  • [Cites] Tumori. 1999 Nov-Dec;85(6):523-5 [10774579.001]
  • [Cites] J Am Coll Surg. 1995 Sep;181(3):193-201 [7670677.001]
  • [Cites] Cancer. 2000 Dec 25;90(6):350-6 [11156518.001]
  • [Cites] In Vivo. 1998 Nov-Dec;12(6):571-8 [9891219.001]
  • [Cites] Head Neck. 2001 Sep;23(9):744-8 [11505484.001]
  • [Cites] Arch Surg. 1963 Jul;87:6-12 [14031784.001]
  • [Cites] HNO. 2000 Jun;48(6):421-9 [10929222.001]
  • [Cites] Eur J Surg Oncol. 1990 Feb;16(1):28-32 [2307240.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Jun;112(6):700-6 [7777355.001]
  • [Cites] J Laryngol Otol. 1990 Apr;104(4):350-1 [2370460.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2002 Jul-Aug;64(4):297-9 [12232480.001]
  • [Cites] Am J Otolaryngol. 1996 Mar-Apr;17(2):102-5 [8820184.001]
  • (PMID = 18066514.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 28
  •  go-up   go-down


14. Miller DD, Cowen EW, Nguyen JC, McCalmont TH, Fox LP: Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol; 2010 Mar;146(3):300-4
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity.
  • BACKGROUND: Voriconazole is a triazole antifungal agent approved by the US Food and Drug Administration for serious fungal infections, including with Aspergillus, Fusarium, Pseudallescheria, and Scedosporium species.
  • In initial clinical trials, approximately 2% of patients developed cutaneous reactions, including photosensitivity, cheilitis, and xerosis.
  • OBSERVATION: We report 5 melanoma in situ lesions in the setting of extreme photosensitivity associated with long-term voriconazole therapy.
  • CONCLUSIONS: We recommend surveillance for skin cancer formation in all patients who require long-term voriconazole treatment, particularly those who manifest signs or symptoms of photosensitivity or chronic photodamage.
  • [MeSH-major] Melanoma / chemically induced. Photosensitivity Disorders / chemically induced. Pyrimidines / adverse effects. Skin Neoplasms / chemically induced. Triazoles / adverse effects
  • [MeSH-minor] Adult. Antifungal Agents / adverse effects. Antifungal Agents / therapeutic use. Biopsy. Chronic Disease. Coccidioidomycosis / drug therapy. Diagnosis, Differential. Ear. Female. Follow-Up Studies. Forearm. Granulomatous Disease, Chronic / drug therapy. Humans. Male. Meningitis, Fungal / drug therapy. Time Factors. Voriconazole. Young Adult

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2010 Mar;146(3):329-31 [20231508.001]
  • (PMID = 20083676.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; JFU09I87TR / Voriconazole
  •  go-up   go-down


15. Kung B, Aftab S, Wood M, Rosen D: Malignant melanoma metastatic to the thyroid gland: a case report and review of the literature. Ear Nose Throat J; 2009 Jan;88(1):E7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma metastatic to the thyroid gland: a case report and review of the literature.
  • The thyroid gland is a relatively uncommon site for a secondary malignancy; even less common is a case of malignant melanoma metastatic to the thyroid.
  • Fine-needle aspiration biopsy (FNAB) identified the mass as a malignant melanoma.
  • The patient had had no known primary skin melanoma.
  • Postoperatively, he declined to undergo radio- and chemotherapy.
  • FNAB again attributed the enlargement to malignant melanoma.
  • He developed ventilator-dependent respiratory failure and required a subtotal thyroidectomy for the placement of a tracheostomy tube.
  • [MeSH-major] Melanoma / secondary. Neoplasm Invasiveness / pathology. Thyroid Neoplasms / secondary. Thyroid Nodule / pathology
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Follow-Up Studies. Humans. Immunohistochemistry. Lymph Nodes / pathology. Male. Neck Dissection. Neoplasm Staging. Risk Assessment. Thyroidectomy / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19172560.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


16. Lee L, Sharma S, Morgan B, Allegrini P, Schnell C, Brueggen J, Cozens R, Horsfield M, Guenther C, Steward WP, Drevs J, Lebwohl D, Wood J, McSheehy PM: Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother Pharmacol; 2006 Jun;57(6):761-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
  • An orthotopic, syngeneic mouse model was used: C57BL/6 mice injected in the ear with murine B16/BL6 melanoma cells which metastases to the cervical lymph-nodes.
  • The primary tumor and spontaneous metastases express VEGF and VEGF receptors and respond to treatment with VEGFR tyrosine kinase inhibitors.
  • In the B16/BL6 model, the active dose of 50 mg/kg PTK/ZK yielded 62.4 (+/- 16.0) h microM plasma exposure, which is comparable to the plasma area under the concentration time curve (AUC) achieved by the 1000 mg dose of PTK/ZK used in clinical trials.
  • Furthermore, at doses of 50 mg/kg PTK/ZK and above, an increase in plasma VEGF level 10 h after drug administration was observed in mice which was consistent with findings from the clinical trials.
  • In conclusion, the preclinical pharmacodynamics of PTK/ZK correlate well with clinical activity in phase I trials over comparable exposures to the drug.
  • [MeSH-major] Colorectal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Melanoma, Experimental / drug therapy. Phthalazines / therapeutic use. Pyridines / therapeutic use. Receptors, Vascular Endothelial Growth Factor / blood
  • [MeSH-minor] Angiogenesis Inhibitors / blood. Angiogenesis Inhibitors / pharmacokinetics. Angiogenesis Inhibitors / therapeutic use. Animals. Biomarkers. Dogs. Drug Evaluation, Preclinical. Female. Humans. Magnetic Resonance Imaging. Mice. Mice, Inbred C57BL. Protein Kinase Inhibitors / blood. Protein Kinase Inhibitors / pharmacokinetics. Protein Kinase Inhibitors / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Rats

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16172907.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Biomarkers; 0 / Phthalazines; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 5DX9U76296 / vatalanib; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


17. Ciralsky J, Colby K: Conjunctival melanomas: can the cancer stem cell hypothesis be applied? Semin Ophthalmol; 2009 May-Jun;24(3):161-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Conjunctival melanoma patients often follow an unpredictable course with significant rates of recurrence and metastases despite optimal treatment.
  • Targeting cancer stem cells may be the key to future treatments.
  • Directed treatments need to focus on key differences between cancer stem cells and normal tissue stem cells.
  • These directed treatments may lead to curative therapies and decrease the number of recurrences and metastases.
  • [MeSH-major] Conjunctival Neoplasms / etiology. Melanoma / etiology. Neoplastic Stem Cells / physiology
  • [MeSH-minor] Angiogenesis Inhibitors / therapeutic use. Animals. Antineoplastic Agents / therapeutic use. Humans. Neovascularization, Pathologic / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19437352.001).
  • [ISSN] 1744-5205
  • [Journal-full-title] Seminars in ophthalmology
  • [ISO-abbreviation] Semin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents
  • [Number-of-references] 31
  •  go-up   go-down


18. Koehl GE, Andrassy J, Guba M, Richter S, Kroemer A, Scherer MN, Steinbauer M, Graeb C, Schlitt HJ, Jauch KW, Geissler EK: Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation; 2004 May 15;77(9):1319-26
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In one tumor-transplant model, BALB/c mice received subcutaneous syngenic CT26 colon adenocarcinoma cells 7 days before C3H ear-heart transplantation.
  • Rapamycin or CsA treatment was initiated with transplantation.
  • In a second model system, a B16 melanoma was established in C57BL/6 mice that received a primary vascularized C3H heart allograft.
  • Similar effects of the drugs occurred with B16 melanomas and primary vascularized C3H allografts in C57BL/6 mice.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibiotics, Antineoplastic / pharmacology. Colonic Neoplasms / drug therapy. Graft Rejection / drug therapy. Heart Transplantation. Sirolimus / pharmacology
  • [MeSH-minor] Animals. Cyclosporine / pharmacology. Drug Therapy, Combination. Immunosuppressive Agents / pharmacology. Male. Melanoma / complications. Melanoma / drug therapy. Mice. Mice, Inbred BALB C. Mice, Inbred C3H. Mice, Inbred C57BL. Mice, SCID. Skin Neoplasms / complications. Skin Neoplasms / drug therapy. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15167584.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


19. Moshfeghi DM, Moshfeghi AA, Finger PT: Enucleation. Surv Ophthalmol; 2000 Jan-Feb;44(4):277-301
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recommending enucleation is one of the most difficult therapeutic decisions in ophthalmology.
  • In some cases of malignancy, cryotherapy, laser photocoagulation, diathermy, chemotherapy, and radiation therapy may be viable alternatives to surgery.
  • Once the decision is made to perform enucleation or evisceration, the surgeon must choose from several types of implants and wrapping materials.
  • These devices can be synthetic, autologous, or eye-banked tissues.
  • Controversies and results of the Controlled Ocular Melanoma Study are summarized.
  • [MeSH-minor] Eye Injuries / surgery. Eye Neoplasms / surgery. Eye, Artificial. Humans. Informed Consent. Intraoperative Complications. Orbital Implants. Postoperative Complications. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10667436.001).
  • [ISSN] 0039-6257
  • [Journal-full-title] Survey of ophthalmology
  • [ISO-abbreviation] Surv Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 305
  •  go-up   go-down


20. Rosenblatt MI, Azar DT: Anti-angiogenic therapy: Prospects for treatment of ocular tumors. Semin Ophthalmol; 2006 Jul-Sep;21(3):151-60
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-angiogenic therapy: Prospects for treatment of ocular tumors.
  • Angiogensis inhibitors that target this switch are in clinical trials for a wide array of tumor types.
  • Evidence for angiogenesis in the growth and spread of uveal melanoma, retinoblastoma, and von Hippel Lindau (VHL) disease exists.
  • The very limited trials of angiogenesis inhibitors in the treatment of uveal melanoma and VHL are promising, although more extensive controlled trials will be needed to confirm their efficacy.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Eye Neoplasms / blood supply. Neovascularization, Pathologic / drug therapy

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912013.001).
  • [ISSN] 0882-0538
  • [Journal-full-title] Seminars in ophthalmology
  • [ISO-abbreviation] Semin Ophthalmol
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / EY10101
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors
  • [Number-of-references] 51
  •  go-up   go-down


21. Biel M: Advances in photodynamic therapy for the treatment of head and neck cancers. Lasers Surg Med; 2006 Jun;38(5):349-55
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in photodynamic therapy for the treatment of head and neck cancers.
  • Photodynamic therapy (PDT) is an FDA-approved minimally invasive medical treatment modality that utilizes light in the presence of oxygen to activate photosensitizing agents that are relatively selectively concentrated in abnormal or neoplastic cells resulting in cell death.
  • At the present time, PDT has been approved for clinical treatment in the United States, European Union, Canada, Russia, and Japan.
  • In the United States, US Food and Drug administration approval has been given for the use of PDT in the treatment of Barrett's esophagus, obstructing esophageal carcinoma and early and obstructing tracheobronchial carcinoma using the photosensitizer Photofrin; actinic keratosis using the photosensitizer Levulan (aminolevulinic acid); and macular degeneration using the photosensitizer BPD.
  • In the EU the above noted indications have also been approved in addition to the treatment of early head and neck cancers and palliative treatment of head and neck cancer using the photosensitizer Foscan; and treatment of basal and squamous cell skin cancers using the photosensitizer Metvix.
  • [MeSH-major] Dihematoporphyrin Ether / therapeutic use. Head and Neck Neoplasms / therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ambulatory Care. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Female. Humans. Male. Melanoma / therapy. Middle Aged. Minnesota / epidemiology. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / therapy. Papilloma / therapy. Retrospective Studies. Sarcoma, Kaposi / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16788923.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


22. Teppone M, Avakyan R: Extremely high-frequency therapy in oncology. J Altern Complement Med; 2010 Nov;16(11):1211-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extremely high-frequency therapy in oncology.
  • OBJECTIVE: This article represents a review of the literature, mainly from Russian sources, dealing with the therapeutic application of low-intensity electromagnetic radiation in the millimeter band applied to experimental and clinical oncology.
  • METHOD: At the early stage of these studies, efficacy and safety of millimeter electromagnetic radiation (extremely high frequency [EHF]) was proved for various types of malignant tumors.
  • RESULTS: Developments led to treatment on skin melanoma, cancer of the ear-nose-throat, bowel and breast cancer, cancer of the uterus, lung, and stomach, solid tumors, as well as lymphoma.
  • The main indications for this therapy are (1) preparation prior to radical treatment;.
  • (2) prevention and treatment of side-effects and complications from chemotherapy and radiotherapy;.
  • (4) treatment of the paraneoplastic syndrome; and (5) palliative therapy of incurable patients.
  • CONCLUSIONS: In spite of the fact that not all mechanisms underlying effects of EHF therapy are known as yet, this therapeutic modality has been shown to have great potential in clinical oncology from studies performed in Eastern Europe and Russia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20973733.001).
  • [ISSN] 1557-7708
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


23. Huang Q, Wu H, Wang Z, Zhang Z, Jia H: [Diagnosis and treatment of lateral skull base tumors in pediatric]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Aug;22(16):734-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of lateral skull base tumors in pediatric].
  • OBJECTIVE: To explore the diagnosis and treatment of lateral skull base tumors in children.
  • One had schwannoma of the trigeminal nerve, one had malignant melanoma, one had fibroma in temporal bone, one had chordoma, two had rhabdomyosarcoma, two had esthesioneuroblastoma.
  • Of 8 patients, one case was treated with chemotherapy.
  • Four patients had pre-and postoperative chemotherapy.
  • Three patients received postoperative chemotherapy.
  • One patient of chordoma died 5 months after surgery, the other 7 patients were alive at the time of analysis.
  • Hearing loss occurred in one patient in the operated ear.
  • One patient developed hoarseness.
  • Two patients developed swallowing obstruction and healed 3-4 months after surgery.
  • Surgery is the first choice of the treatment for lateral skull base tumors.
  • Radiation therapy and chemotherapy could be used for malignant tumors preoperatively and postoperatively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18975775.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


24. Feldman RJ, Maize JC: Multiple keratoacanthomas in a young woman: report of a case emphasizing medical management and a review of the spectrum of multiple keratoacanthomas. Int J Dermatol; 2007 Jan;46(1):77-9
Hazardous Substances Data Bank. ACITRETIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since then, she had not had any treatment or biopsies, and stated that she had not suffered from any health problems during the intervening period.
  • The family history was negative for skin diseases, including melanoma, nonmelanoma skin cancer, psoriasis, and eczema, and positive for Type II diabetes mellitus.
  • The patient's only medication was Ortho-Tricyclene birth control pills.
  • She had no known drug allergies.
  • A similar lesion was present in the scaphoid fossa of the left ear and smaller lesions were scattered on her face.
  • Overall, there appeared to be two distinct types of lesion.
  • One type appeared round, oval, and symmetric with a central keratotic plug, similar to that on the ear.
  • The other type was larger, more exophytic, and verrucous, including the lesions on the volar surfaces.
  • In anticipation of starting oral retinoid therapy for her multiple keratoacanthomas, she was referred to her primary care physician for control of hyperlipidemia.
  • [MeSH-minor] Acitretin / therapeutic use. Adult. Biopsy. Female. Humans. Isotretinoin / therapeutic use. Keratolytic Agents / therapeutic use. Nicotinic Acids / therapeutic use

  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Dermatol. 2007 Oct;46(10):1105 [17910728.001]
  • (PMID = 17214727.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratolytic Agents; 0 / Nicotinic Acids; 81BDR9Y8PS / tazarotene; EH28UP18IF / Isotretinoin; LCH760E9T7 / Acitretin
  • [Number-of-references] 20
  •  go-up   go-down


25. Yang SX, Kummar S, Steinberg SM, Murgo AJ, Gutierrez M, Rubinstein L, Nguyen D, Kaur G, Chen AP, Giranda VL, Tomaszewski JE, Doroshow JH, National Cancer Institute Phase 0 Working Group: Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. Cancer Biol Ther; 2009 Nov;8(21):2004-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas.
  • PURPOSE: Targeting the poly (ADP-ribose) polymerase (PARP) pathway for cancer treatment has been an active area of pre-clinical and clinical research.
  • We aimed to determine whether the PARP inhibitor ABT-888 hits its therapeutic target in tumors by immunohistochemistry during a Phase 0 trial conducted at the National Cancer Institute.
  • EXPERIMENTAL DESIGN: The expression of poly (ADP-ribose) (PAR) and full size PARP-1 were quantitatively examined by immunohistochemistry in paraffin-embedded tumor biopsies at baseline and 3-24 h after a single oral dose (25 or 50 mg) of ABT-888.
  • RESULTS: Baseline PAR levels were moderate to high in three patients with non-Hodgkin lymphomas, and one each with small cell lung cancer, squamous cell carcinoma of the tongue and melanoma; low in two patients with cutaneous T-cell lymphoma and one with adenocarcinoma of external ear canal.
  • A significant decrease in PAR (median decrease 30.2, range -13.1 to -69.8) was achieved after drug administration (n = 6 pairs; p = 0.03), whereas an increase in PARP-1 expression was observed in five of the six tumors.
  • This resulted in a decrease in the ratio of PAR to PARP-1 in tumor biopsies (median -6.76, range -0.41 to -22.59; p = 0.03).
  • CONCLUSIONS: ABT-888 hits its therapeutic target by significantly reducing PAR levels and the ratio of PAR to PARP-1 in human tumor cells detected by immunohistochemistry.
  • Baseline tumor PAR levels vary considerably among patients who entered this phase 0 study.
  • This underscores a need to investigate baseline PAR levels in association with response in future preclinical and clinical studies.
  • [MeSH-major] Benzimidazoles / pharmacology. Enzyme Inhibitors / pharmacology. Lymphoma / drug therapy. Neoplasms / drug therapy. Neoplasms / enzymology. Poly(ADP-ribose) Polymerase Inhibitors
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Drug Resistance, Neoplasm. Humans. Immunohistochemistry. Poly(ADP-ribose) Polymerases / biosynthesis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2009 Nov;8(21):2010-2 [20037466.001]
  • (PMID = 19823047.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzimidazoles; 0 / Enzyme Inhibitors; 0 / Poly(ADP-ribose) Polymerase Inhibitors; 01O4K0631N / veliparib; EC 2.4.2.30 / PARP1 protein, human; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  •  go-up   go-down


26. Jiang HQ, Wang Y, Hu XB, Li YS, Li JS: Composite tissue allograft transplantation of cephalocervical skin flap and two ears. Plast Reconstr Surg; 2005 Mar;115(3):31e-35e; discussion 36e-37e
Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite tissue allograft transplantation of cephalocervical skin flap and two ears.
  • [MeSH-major] Ear Neoplasms / surgery. Ear, External / transplantation. Melanoma / surgery. Scalp / transplantation. Skin Neoplasms / surgery. Surgical Flaps
  • [MeSH-minor] Aged. Anastomosis, Surgical. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Drug Therapy, Combination. Female. Graft Rejection / prevention & control. Humans. Immunoglobulin G / therapeutic use. Immunosuppressive Agents / therapeutic use. Microsurgery. Mycophenolic Acid / analogs & derivatives. Mycophenolic Acid / therapeutic use. Reconstructive Surgical Procedures. Tacrolimus / therapeutic use. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Plast Reconstr Surg. 2006 Jul;118(1):268-70 [16816716.001]
  • (PMID = 15731658.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Immunoglobulin G; 0 / Immunosuppressive Agents; 9242ECW6R0 / mycophenolate mofetil; CUJ2MVI71Y / daclizumab; HU9DX48N0T / Mycophenolic Acid; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


27. Finger PT, Chin KJ: Intravitreous ranibizumab (lucentis) for radiation maculopathy. Arch Ophthalmol; 2010 Feb;128(2):249-52
Hazardous Substances Data Bank. PALLADIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Brachytherapy / adverse effects. Macula Lutea / radiation effects. Radiation Injuries / drug therapy. Retinal Diseases / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Choroid Neoplasms / radiotherapy. Female. Fluorescein Angiography. Humans. Injections. Macular Edema / drug therapy. Macular Edema / etiology. Male. Melanoma / radiotherapy. Middle Aged. Palladium / adverse effects. Radioisotopes / adverse effects. Ranibizumab. Retinal Hemorrhage / drug therapy. Retinal Hemorrhage / etiology. Retinal Neovascularization / drug therapy. Retinal Neovascularization / etiology. Tomography, Optical Coherence. Visual Acuity. Vitreous Body

  • MedlinePlus Health Information. consumer health - Retinal Disorders.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20142553.001).
  • [ISSN] 1538-3601
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00750399
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Radioisotopes; 5TWQ1V240M / Palladium; ZL1R02VT79 / Ranibizumab
  •  go-up   go-down






Advertisement